IPD subgroup analyses of vitamin D3 supplementation and cancer mortality in the general population by age, sex, BMI, ethnicity, vitamin D baseline level, cancer diagnosis in five years prior baseline, and adherence in all trials (panel A, main analysis) and restricted to trials with a daily dosing regimen (panel B, post-hoc analysis). Note: No studies available for “Cancer diagnosis up to 5 years prior baseline” = yes.